Pasar al contenido principal

DESARROLLO DE UN ENSAYO MICROFLUIDICO FUNCIONAL EN CELULAS PARA EL TRATAMIENTO PERSONALIZADO CONTRA EL CANCER

RTI2018-094533-A-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia

  • Manzano-Muñoz, A.
  • Alcon, Clara
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Seyfried, F.
  • Debatin, K.M.
  • Meyer, L.H.
  • Samitier, J.
  • Montero, J.
Multiple targeted therapies are currently explored for pediatric and young adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment. However, this new armamentarium of therapies faces an old problem: choosing the right treatment for each patient. The lack of predictive biomarkers is particularly worrying for pediatric patients since it impairs the implementation of new treatments in the clinic. In this study, we used the functional assay dynamic BH3 profiling (DBP) to evaluate two new treatments for BCP-ALL that could improve clinical outcome, especially for relapsed patients. We found that the MEK inhibitor trametinib and the multi-target tyrosine kinase inhibitor sunitinib exquisitely increased apoptotic priming in an NRAS-mutant and in a KMT2A-rearranged cell line presenting a high expression of FLT3, respectively. Following these observations, we sought to study potential adaptations to these treatments. Indeed, we identified with DBP anti-apoptotic changes in the BCL-2 family after treatment, particularly involving MCL-1 - a pro-survival strategy previously observed in adult cancers. To overcome this adaptation, we employed the BH3 mimetic S63845, a specific MCL-1 inhibitor, and evaluated its sequential addition to both kinase inhibitors to overcome resistance. We observed that the metronomic combination of both drugs with S63845 was synergistic and showed an increased efficacy compared to single agents. Similar observations were made in BCP-ALL KMT2A-rearranged PDX cells in response to sunitinib, showing an analogous DBP profile to the SEM cell line. These findings demonstrate that rational sequences of targeted agents with BH3 mimetics, now extensively explored in clinical trials, may improve treatment effectiveness by overcoming anti-apoptotic adaptations in BCP-ALL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

  • Alcon, Clara
  • Martín, Fernando|||0000-0002-3496-9093
  • Prada, Estela|||0000-0003-4611-1120
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Soriano, Aroa|||0000-0001-9659-1471
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
  • Samitier, Josep|||0000-0002-1140-3679
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Montero, Joan|||0000-0002-9192-4836
Targeted agents have emerged as promising molecules for cancer treatment, but most of them fail to achieve complete tumor regression or attain durable remissions due to tumor adaptations. We used dynamic BH3 profiling to identify targeted agents effectiveness and anti-apoptotic adaptations upon targeted treatment in rhabdomyosarcoma. We focused on studying the use of BH3 mimetics to specifically inhibit pro-survival BCL-2 family proteins, overwhelm resistance to therapy and prevent relapse. We observed that the MEK1/2 inhibitor trametinib rapidly depleted the pro-apoptotic protein NOXA, thus increasing MCL-1 availability. Indeed, we found that the MCL-1 inhibitor S63845 synergistically enhanced trametinib cytotoxicity in rhabdomyosarcoma cells in vitro and in vivo. In conclusion, our findings indicate that the combination of a BH3 mimetic targeting MCL-1 with trametinib improves efficiency on rhabdomyosarcoma by blocking tumor adaptation to treatment.